Multicenter Randomized Trial Evaluating FOLFIRI Plus Cetuximab Versus FOLFIRI Plus Bevacizumab in First Line Treatment of Metastatic Colorectal Cancer.

Trial Profile

Multicenter Randomized Trial Evaluating FOLFIRI Plus Cetuximab Versus FOLFIRI Plus Bevacizumab in First Line Treatment of Metastatic Colorectal Cancer.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 15 Sep 2017

At a glance

  • Drugs Cetuximab (Primary) ; Bevacizumab; Fluorouracil; Folinic acid; Irinotecan
  • Indications Adenocarcinoma; Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms FIRE-3
  • Most Recent Events

    • 12 Sep 2017 Results presented at the 42nd European Society for Medical Oncology Congress.
    • 23 Aug 2017 Results of a retrospective exploratory analysis assessing survival across several treatment lines in metastatic colorectal cancer patients (data cut off: 22 Aug 2014), published in the European Journal of Cancer.
    • 06 Jun 2017 Results assessing genetic polymorphisms in the CCL5/CCR5 axis to predict efficacy of cetuximab (CET)-based first-line treatment using samples of two different cohorts of patients (n=491) with KRAS wild-type metastatic colorectal cancer, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top